SciClone And Sigma-Tau Announce Additional Positive Results In Clinical Study Examining ZADAXIN’s Ability To Enhance Response To H1N1 Vaccine

How to reduce your risk of contracting swine flu:

Do not travel to areas known to be affected.

Minimize the amount of time spent on public transport especially aeroplanes.

Avoided crowded public places, especially those using recirculated air conditioned air

Wear a surgical grade face mask and ensure it is fitted correctly so that it covers your nose as well as your mouth.

Refrain from touching your mouth with your hands or fingers if they may have come into contact with surfaces contiminated with the virus.

Carefully wipe any surfaces that may have come into contact with carriers such as door handles, toilet flushers, work surfaces and telephones

SciClone And Sigma-Tau Announce Additional Positive Results In Clinical Study Examining ZADAXIN’s Ability To Enhance Response To H1N1 Vaccine

SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) and its partner Sigma-Tau S.p.A., announced additional topline results in a clinical study evaluating the potential of ZADAXIN® (thymalfasin) to enhance immune response to the MF59 adjuvanted H1N1 influenza monovalent vaccine, Focetria™ from Novartis. According to investigators, ZADAXIN treatment given with the H1N1 vaccine led to a statistically significant (p value=0.04) increase in the percentage of subjects who seroconverted, also when evaluated 42 days after vaccination, compared to those who received the H1N1 vaccine alone... (Source: Health News from Medical News Today)

Comments are closed.

Current Status

Protection Steps

SciClone And Sigma-Tau Announce Additional Positive Results In Clinical Study Examining ZADAXIN’s Ability To Enhance Response To H1N1 Vaccine

Flu Protection

Recent Features